K., Tripathi, M
2013:972913 10.1155/2013/972913 [DOI] [PMC free article] [PubMed] [Google Scholar] Villablanca J.G., Volchenboum S.L., Cho H., Kang M.H., Cohn S.L., Anderson C.P., Marachelian A., Groshen S., Tsao-Wei D., Matthay K.K., et al
Chandra, A.R
For PT-141, the evidence is strongest: its FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in women, and it has meaningful off-label use in men for erectile and libido issues that dont respond to PDE5 inhibitors
Liposovit liposomal technology provides a solution to this
Both fall within the range that studies show can be effectively delivered intranasally, though the smaller BPC-157 may achieve somewhat higher bioavailability through this route